Solid IO, a Helsinki-based medtech company specializing in patient-specific organ-on-chip technology, has closed €800,000 in equity funding. The round was led by Nordic Science Investments and included funding from BSV Ventures, Helsinki University Funds. Solid IO shared the details with AIN.
About Solid IO
-
Founded in January 2025 by Noora Hujala and Dr. Heidi Haikala, Solid IO develops a tumor-on-chip platform that replicates the patient’s tumor microenvironment, generating high-accuracy, real-time data on how individual cancers respond to immunotherapies and combination treatments.
-
By integrating bioengineering and organ-on-chip technology, the platform helps clinicians select the most effective therapy from day one, improving patient outcomes while reducing unnecessary side effects.
-
The technology offers early patient stratification, biomarker validation, and treatment-response modeling, helping pharmaceutical companies reduce trial timelines, optimize patient selection, and accelerate the development of new immuno-oncology drugs.
"Every cancer patient deserves a treatment plan based on their unique biology, adapting throughout the treatment journey. We are eliminating trial-and-error in cancer immunotherapy by bringing patient-specific tumor models into clinical use – this is the next evolution in precision oncology," says Noora Hujala, CEO and co-founder of Solid IO.
Investment details
The round was led by Nordic Science Investments and included funding from BSV Ventures, Helsinki University Funds, and an undisclosed private European investor.
-
Finland’s Nordic Science Investments (NSI) is a capital investment fund specializing in university spin-out companies during pre-seed, seed, and Series A funding rounds. NSI provides financial capital, mentorship, networking opportunities, and assistance with commercialization efforts.
-
BSV Ventures is a venture capital fund specialising in Deep Tech, Life Science, and Dual-Use investments. With a focus on breakthrough critical technologies and a strong commitment to the Baltic Sea region (Nordics, Baltics, and CEE), BSV empowers entrepreneurs to solve global challenges and drive technological advancements across diverse industries.
"The possibility to predict individual patient responses to immunotherapies before treatment is a game-changer. By replicating how real tumors interact with the immune system, we are bridging the gap between research and clinical application - bringing us closer to truly personalized oncology," said Dr. Heidi Haikala CSO and co-founder of Solid IO.
This investment accelerates the development of Solid IO’s breakthrough technology that allows personalized cancer treatment and immunotherapy advancements.
